Not To Be Sniffed At: Dupixent Success In Rhinosinusitis Could Open Up Large Additional Market
Executive Summary
On the brink of an expanded US approval for asthma, Sanofi/Regeneron’s interleukin-4 receptor blocker Dupixent has produced positive topline Phase III data in a lucrative third indication, rhinosinusitis with nasal polyps.
You may also be interested in...
Keeping Track: Vascepa Adds CV Risk Reduction Claim And Submissions Pour Into FDA
The latest drug development news and highlights from our US FDA Performance Tracker.
Triple Threat: Full Rhinosinusitis Data Place Dupixent Top Of The IL Heap
Sanofi and Regeneron take a big step forward to building an allergy franchise off the back of newly released data from latest Dupixent trials in severe chronic rhinosinusitis with nasal polyps.
Keeping Track: Pfizer’s Talzenna Ensures Record Year For Novel US Approvals; Novartis Submits SMA Gene Therapy
The latest drug development news and highlights from our FDA Performance Tracker.